DOI: 10.1101/516351Jan 9, 2019Paper

Neuroendocrine negative SCLC is mostly RB1 WT and may be sensitive to CDK4/6 inhibition

BioRxiv : the Preprint Server for Biology
Dmitriy SonkinBeverly A Teicher

Abstract

Small cell lung cancer (SCLC) is an aggressive form of lung cancer with limited therapeutic options, a very high mortality rate and is characterized, in most cases, by neuroendocrine features. A small but important subset of SCLC has intact RB1. However, other characteristics of this subset are not well-defined. To comprehensively assess the underlying genomics of SCLC cell lines with functional RB1, we examined 48 SCLC cell lines from the Cancer Cell Line Encyclopedia (CCLE) collection. Out of these 48 SCLC cell lines, 8 were found to be RB1 WT. We found that RB1 WT SCLC lines are enriched for loss of neuroendocrine lineage markers with CDKN2A inactivation, or CCND1 amplification. Six RB1 WT SCLC cell lines were included in NCI SCLC drug sensitivity screen and two of them were sensitive to CDK4/6 inhibition.

Related Concepts

Biological Markers
Cell Line, Tumor
Small Cell Carcinoma of Lung
Neuroendocrine Tumors
Malignant Neoplasm of Lung
Cyclin-Dependent Kinase 4
Carcinoma, Small Cell
Treatment Options
RB1 gene
Genomics

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

Related Papers

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Liang WangPing Yang
Annals of Oncology : Official Journal of the European Society for Medical Oncology
A Ardizzoni, F Grossi
© 2021 Meta ULC. All rights reserved